IIA(Glc) allosteric control of Escherichia coli glycerol kinase: binding site cooperative transitions and cation-promoted association by Zinc(II).

The catalytic activity of glycerol kinase (EC 2.7.1.30, ATP:glycerol 3-phosphotransferase) from Escherichia coli is inhibited allosterically by IIA(Glc) (previously known as III(Glc)), the glucose-specific phosphocarrier protein of the phosphoenolpyruvate:glycose phosphotransferase system. A sequentially contiguous portion of glycerol kinase undergoes an induced fit conformational change involving coil, alpha-helix, and 3(10)-helix upon IIA(Glc) binding. A second induced fit occurs upon binding of Zn(II) to a novel intermolecular site, which increases complex stability by cation-promoted association. Eight of the ten sequentially contiguous amino acids are substituted with alanine to evaluate the roles of these positions in complex formation. Effects of the substitutions reveal both favorable and antagonistic contributions of the normal amino acids to complex formation, and Zn(II) reverses these contributions for two of the amino acids. The consequences of some of the substitutions for IIA(Glc) inhibition are consistent with changes in the intermolecular interactions seen in the crystal structures. However, for the amino acids that are located in the region that is alpha-helical in the absence of IIA(Glc), the effects of the substitutions are not consistent with changes in intermolecular interactions but with increased stability of the alpha-helical region due to the higher alpha-helix propensity of alanine. The reduced affinity for IIA(Glc) binding seen for these variants is consistent with predictions of Freire and co-workers [Luque, I., and Freire, E. (2000) Proteins: Struct., Funct., Genet. 4, 63-71]. These variants show also increased cation-promoted association by Zn(II) so that the energetic contribution of Zn(II) to complex formation is doubled. The similarity of effects of the alanine substitutions of the amino acids in the alpha-helical region for IIA(Glc) binding affinity and cation-promoted association by Zn(II) indicates that they function as a cooperative unit.

Subcloning, expression, purification, and characterization of Haemophilus influenzae glycerol kinase.

Glycerol kinase (EC 2.7.1.30) is a bacterial sugar kinase and a member of the sugar kinase/actin/hsc-70 superfamily of enzymes. The enzyme from Escherichia coli is an allosteric regulatory enzyme whose activity is inhibited by fructose 1,6-bisphosphate (FBP) and the glucose-specific phosphocarrier of the phosphoenolpyruvate:glycose phosphotransferase system, IIA(Glc) (previously termed III(Glc)). Comparison of its primary structure with that of the highly similar Haemophilus influenzae glycerol kinase reveals that the amino acid sequence for the binding site for FBP is conserved while the amino acid sequence for the binding site for IIA(Glc) contains differences that are predicted to prevent its inhibition. To test this hypothesis, the H. influenzae glpK gene was assembled from DNA library fragments and subcloned into pUC18. The enzyme is expressed at high levels in E. coli. It was purified to greater than 90% homogeneity by taking advantage of its solubility behavior in a procedure that requires no column chromatography. The initial-velocity kinetic parameters of the purified enzyme are similar to those of the E. coli glycerol kinase. The H. influenzae glycerol kinase is inhibited by FBP but not by IIA(Glc), in agreement with the prediction based on sequence comparison. Sedimentation velocity experiments reveal that inhibition of HiGK by FBP is associated with oligomerization, behavior which is similar to EcGK. The possibility of utilizing mutagenesis studies to exploit the high degree of similarity of these two enzymes to elucidate the mechanism of allosteric regulation by IIA(Glc) is discussed.

Reverse genetics of Escherichia coli glycerol kinase allosteric regulation and glucose control of glycerol utilization in vivo.

Reverse genetics is used to evaluate the roles in vivo of allosteric regulation of Escherichia coli glycerol kinase by the glucose-specific phosphocarrier of the phosphoenolpyruvate:glycose phosphotransferase system, IIA(Glc) (formerly known as III(glc)), and by fructose 1,6-bisphosphate. Roles have been postulated for these allosteric effectors in glucose control of both glycerol utilization and expression of the glpK gene. Genetics methods based on homologous recombination are used to place glpK alleles with known specific mutations into the chromosomal context of the glpK gene in three different genetic backgrounds. The alleles encode glycerol kinases with normal catalytic properties and specific alterations of allosteric regulatory properties, as determined by in vitro characterization of the purified enzymes. The E. coli strains with these alleles display the glycerol kinase regulatory phenotypes that are expected on the basis of the in vitro characterizations. Strains with different glpR alleles are used to assess the relationships between allosteric regulation of glycerol kinase and specific repression in glucose control of the expression of the glpK gene. Results of these studies show that glucose control of glycerol utilization and glycerol kinase expression is not affected by the loss of IIA(Glc) inhibition of glycerol kinase. In contrast, fructose 1,6-bisphosphate inhibition of glycerol kinase is the dominant allosteric control mechanism, and glucose is unable to control glycerol utilization in its absence. Specific repression is not required for glucose control of glycerol utilization, and the relative roles of various mechanisms for glucose control (catabolite repression, specific repression, and inducer exclusion) are different for glycerol utilization than for lactose utilization.

Differential expression of thyroid hormone receptor isoforms by thyroid hormone and lithium in rat GH3 and B103 cells.

BACKGROUND: The interaction between lithium, a mood stabilizer, and the thyroid axis has been extensively studied; however, the regulation of thyroid hormone receptors by lithium is yet to be investigated. METHODS: To test whether lithium affects thyroid hormones at the receptor level, we examined the effects of lithium in combination with triiodothyronine (T3) on gene expression of thyroid hormone receptor isoforms in GH3 and B103 cells. RESULTS: The pattern of expression as well as the magnitude of regulation of the different thyroid hormone receptor isoforms appeared to be cell line specific. Whereas T3 regulated all four isoforms in GH3 cells at both time points, T3 did not alter thyroid hormone receptor TR alpha 1 and TR alpha 2 mRNA in B103 cells. Addition of lithium to thyroid hormone-deficient GH3 cells decreased TR alpha 1, alpha 2, and beta 2 expression without affecting TR beta 1 expression at 2 but not 5 days. Addition of lithium to T3-treated GH3 cells did not further modulate gene expression of TR alpha 1, alpha 2, beta 1, or beta 2 when compared to cells treated with T3 alone. The effects of lithium in B103 cells appeared to be isoform specific as well as time dependent, since TR alpha 1 expression was selectively decreased in B103 cells, when treated with T3 in the presence of lithium. CONCLUSIONS: The present study provides direct evidence that T3 and/or lithium regulate TR gene expression in vitro in a both time-dependent and cell line-specific manner.

Lithium administration affects gene expression of thyroid hormone receptors in rat brain.

Even though lithium has received wide attention in the treatment of manic depressive illness, the mechanisms underlying its mood stabilizing effects are not understood. Lithium is known to interact with the thyroid axis and causes hypothyroidism in a subgroup of patients, which compromises its mood stabilizing effects. Since lithium was recently reported to alter thyroid hormone metabolism in the rat brain, the present study investigated whether these effects were mediated through regulation of thyroid hormone receptor (THR) gene expression. Adult male euthyroid rats were either given a diet containing 0.25% lithium or one without lithium for 14 days. Rats were sacrificed in the evening and RNA was isolated from different brain regions to quantitate the isoform specific mRNAs of THRs. Following 14 days of lithium treatment, THR alpha1 mRNA levels were increased in the cortex and decreased in hypothalamus; THR alpha2 mRNA levels were increased in the cortex and THR beta mRNA levels were decreased in the hypothalamus. No significant difference in the expression of these THR isoforms was observed in the hippocampus or cerebellum. Thus, chronic lithium treatment appeared to regulate THR gene expression in a subtype and region specific manner in the rat brain. It remains to be determined whether the observed effects of lithium on THR gene expression are related to its therapeutic efficacy in the treatment of bipolar disorder.

Acute depletion of serotonin down-regulates serotonin transporter mRNA in raphe neurons.

Serotonin transporter (5-HTT) mRNA and 5-HTT sites were measured 3 days after treatment with p-chlorophenylalanine, a tryptophan hydroxylase inhibitor. While 5-HTT mRNA levels decreased (P < 0.001) in the dorsal raphe nucleus, 5-HTT binding sites remained unchanged, suggesting that an acute depletion of 5-HT may induce an increase in the turnover of 5-HTT mRNA without affecting protein levels at 3 days.

Altered serotonin transporter sites in Alzheimer's disease raphe and hippocampus.

This study measured serotonin transporter (5-HTT) sites in the dorsal raphe nucleus (DRN) and hippocampus in Alzheimer's disease (AD). 5-HTT sites were significantly decreased in the DRN in AD, with significant reductions occurring in the lateral wings of the DRN complex. A significant reduction in 5-HTT sites were also observed in the CA2 subfield of the hippocampus and in the entorhinal cortex in AD. The results indicate that the integrity of 5-HT neurons in the DRN may be compromised in AD, and that region specific alterations in 5-HTT sites may occur in the hippocampal complex in AD.